Health‐related quality of life in long‐term survivors with localised prostate cancer by therapy—Results from a population‐based study
| Autor: | Sylke Ruth Zeissig, Lena Koch-Gallenkamp, Salome Adam, Bernd Holleczek, Andrea Eberle, Volker Arndt, Mechthild Waldeyer-Sauerland, Heike Bertram, Annika Waldmann, Sabine Rohrmann, Hermann Brenner, Ron Pritzkuleit |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology medicine.medical_specialty Antineoplastic Agents Hormonal Health Status medicine.medical_treatment Population Androgen deprivation therapy 03 medical and health sciences Prostate cancer 0302 clinical medicine Cancer Survivors Quality of life Internal medicine medicine Humans education Aged Prostatectomy Health related quality of life education.field_of_study Radiotherapy business.industry Prostatic Neoplasms Middle Aged Social Participation medicine.disease Combined Modality Therapy humanities Radiation therapy Population based study Sexual Dysfunction Physiological 030220 oncology & carcinogenesis Multivariate Analysis Linear Models Quality of Life business |
| Zdroj: | European Journal of Cancer Care. 28 |
| ISSN: | 1365-2354 0961-5423 |
| Popis: | OBJECTIVE Several therapies for localised prostate cancer (PC) are available; all yield similar survival rates. However, each therapy has significant side effects that can influence patients' health-related quality of life (HRQoL) in the long run. METHODS The study sample included 911 survivors with localised PC, 5-15 years post-diagnosis who were identified from the population-based CAESAR + study in Germany. HRQoL was assessed using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires. The association between type of therapy and HRQoL was assessed with multivariable linear regression and global F-test adjusting for age, time since diagnosis and comorbidities. RESULTS Overall, survivors treated with radical prostatectomy (RP) or radiotherapy (RT) alone reported the best HRQoL and the lowest symptom burden. Conversely, survivors treated with androgen deprivation therapy (ADT) (& RP/RT) or RP & RT (in combination) reported the worst HRQoL and the highest symptom burden. Significant differences among treatment groups in HRQoL were found for global health status (p = 0.041), social functioning (p = 0.007), urinary symptoms (p = 0.035), bowel symptoms (p = 0.017) and hormonal treatment-related symptoms (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|